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Abstract
Infectious prion aggregates can propagate from extraneural sites into the brain with remarkable efficiency, likely
transported via peripheral nerves. Yet not all prions spread into the brain, and the physical properties of a prion
that is capable of transit within neurons remain unclear. We hypothesized that small, diffusible aggregates spread
into the CNS via peripheral nerves. Here we used a structurally diverse panel of prion strains to analyze how the
prion conformation impacts transit into the brain. Two prion strains form fibrils visible ultrastructurally in the brain
in situ, whereas three strains form diffuse, subfibrillar prion deposits and no visible fibrils. The subfibrillar strains had
significantly higher levels of soluble prion aggregates than the fibrillar strains. Primary neurons internalized both the
subfibrillar and fibril-forming prion strains by macropinocytosis, and both strain types were transported from the
axon terminal to the cell body in vitro. However in mice, only the predominantly soluble, subfibrillar prions, and not
the fibrillar prions, were efficiently transported from the tongue to the brain. Sonicating a fibrillar prion strain
increased the solubility and enabled prions to spread into the brain in mice, as evident by a 40% increase in the
attack rate, indicating that an increase in smaller particles enhances prion neuroinvasion. Our data suggest that the
small, highly soluble prion particles have a higher capacity for transport via nerves. These findings help explain how
prions that predominantly assemble into subfibrillar states can more effectively traverse into and out of the CNS,
and suggest that promoting fibril assembly may slow the neuron-to-neuron spread of protein aggregates.
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Introduction
Misfolded proteins incite cognitive and motor decline in
Alzheimer’s, Parkinson’s, and prion disease. During a
prion infection, prion aggregates, PrPSc, template the
misfolding of the cellular prion protein, PrPC, in an
autocatalytic process that terminates in rapidly progres-
sive and fatal neurodegeneration [1, 39]. Distinct PrPSc
conformers drive PrPC to misfold into a remarkable
range of structural variants that correlate to profoundly
different disease phenotypes [9]. Although most infec-
tious prions spread from peripheral entry sites into the
central nervous system (CNS), certain prion subtypes,
such as variant Creutzfeldt-Jakob disease (vCJD),
replicate and persist in lymphoid organs and fail to neu-
roinvade in mice [5, 14]. An estimated 1:2000 humans in
the UK harbor vCJD prions in lymphoid tissues [20] and
some individuals may remain lifelong subclinical carriers
of extraneural infectious prions with no spread into the
CNS. The physical properties of a prion aggregate that
facilitate CNS entry and spread are unclear.
Peripheral nerves have been implicated as a major
route for prion invasion of the CNS from extraneural
entry sites, a process known as neuroinvasion. First,
prions have been shown to spread from initial exposure
sites into the brain by defined neuroanatomic pathways.
For example, ingestion of prions induces early prion
accumulation in the dorsal motor nucleus of the vagus
and solitary tract nucleus in the brain as well as in the
thoracic spinal cord, consistent with neuron-to-neuron
spread via vagal and splanchnic nerve circuitry [4, 34].
Second, prions replicate in lymphoid tissues in early dis-
ease, prior to CNS invasion, and manipulation of the
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splenic innervation also indicates nerves as a possible
conduit for prion trafficking into the CNS. For example,
juxtaposing splenic nerves and prion-infected follicular
dendritic cells (FDCs) [38], or increasing splenic innerv-
ation, accelerates prion spread to the brain in mouse
models [21]. Finally, sympathectomy delays or prevents
scrapie in mice [21], again suggesting an important role
for peripheral nerves in prion neuroinvasion.
There are many details of protein aggregate spread in
vivo that are not yet well understood, such as which
PrPSc conformers transit in nerves. An advantage to
investigating prion disease in mouse models is the highly
reproducible incubation period and brain regions tar-
geted by distinct prion conformational variants [18, 19],
enabling studies linking PrPSc biophysical properties
with disease phenotype. Although earlier studies demon-
strated that certain prions show a limited capacity to
spread via neurons into the CNS, the properties of prion
aggregates that successfully traffic within nerves are
unknown. We previously identified two mouse-adapted
prion strains that failed to spread to the CNS following
an intraperitoneal (IP) challenge of mice, and three prion
strains that were highly neuroinvasive (NI) [7]. Both
non-NI strains formed fibrillar, congophilic plaques in
the brain after intracerebral (IC) inoculation, while the
NI strains formed diffuse, noncongophilic aggregates
that were less stable in chaotropes and lacked fibrils in
the brain in situ, suggesting that a fibrillar structure cor-
related with poor neuroinvasion. Ultrastructural
characterization of the fibrillar prions has been previ-
ously performed, and fibrillar prion strains were shown
to form classical “kuru” type plaques composed of a
central core of bundles [7, 25, 26, 28, 41]. Interestingly,
GPI-anchorless prions form large fibrillar plaques and
are also poorly neuroinvasive from peripheral exposure
sites; in one study, the authors suggested that the
GPI-anchor on the prion protein was important for
prion transport via nerves [30]. Although some of these
data may collectively argue that fibrillar prions show
inefficient neuroinvasion, there is still no consensus on
the physical requirements for prion entry into the CNS.
Here we investigated the biophysical requirements for
prion uptake and axonal transport in vitro using primary
neurons, as well as prion neuroinvasion in vivo from a
highly-innervated, extraneural exposure site, the tongue.
Materials and methods
Prion inoculation of mice with diverse strains
WT (VM/Dk) or tga20 (Sv129/C57BL/6) mice (groups
of 4-10 male and female mice, 2-3 months old) were
inoculated intracerebrally into the left parietal cortex or
intra-tongue with 10% or 1% prion-infected brain
homogenate prepared from the brains of terminally ill
mice. Tga20 mice express the Prnpa sequence variant
and develop prion disease after a short incubation
period, for example, after IC inoculation, mCWD prions
induce disease in 160 days in tga20 mice, but more than
500 days in WT mice. VM/DK mice express the Prnpb
sequence variant [35] and are highly susceptible to 87V
fibrillar and 22L subfibrillar prion strains.
Mice expressing PrP under the NSE promoter, as
well as Prnp-/- mice, were a kind gift from Dr.
Adriano Aguzzi. NSE-PrP mice on a Prnp-/- back-
ground express more than 1.5-fold higher PrPC than
WT in cerebral hemispheres [22]. Mice were main-
tained under specific pathogen-free conditions on a
12:12 light/dark cycle (2 – 5 mice per cage) and were
monitored three times weekly.
Strains 22L and ME7, as well as RML, are mouse-
adapted prions originally derived from sheep scrapie that
have different cellular targets in the brain and diverse
plaque morphologies [11], and were kind gifts from Drs.
Michael Oldstone and Adriano Aguzzi, respectively.
Mouse-adapted CWD (mCWD) was derived from fifth
passage of deer CWD in tga20 mice [41].
TSE was diagnosed according to clinical criteria in-
cluding ataxia, kyphosis, stiff tail, hind leg clasp, and
hind leg paresis. Mice were sacrificed at early timepoints
(50 and 75% of the incubation period) or at the onset of
terminal disease. The brain was halved, and one hemi-
brain was formalin-fixed for 2-3 days, then immersed in
96% formic acid for 1 h, washed in water, and post-fixed
in formalin for 2-4 days. Brains were then cut into 2 mm
transverse sections and paraffin-embedded for histo-
logical analysis. The remaining hemi-brain was cut and a
2-3 mm transverse section at the level of the hippocam-
pus/thalamus was embedded in OCT and immediately
frozen on dry ice. The remaining brain sections were
frozen for biochemical analyses. No mice were excluded
from the analysis.
Histopathology and immunohistochemical stains
Four μm sections of brain were cut onto positively
charged silanized glass slides and stained with
hematoxylin and eosin or immunostained using antibodies
for PrP (SAF84). For PrP staining, sections were deparaffi-
nized and incubated for 5 min in 96% formic acid, then
washed in water for 5 min, treated with 5 μg/ml of
proteinase-K for 7 min, and washed in water for 5 min.
Sections were then placed in citrate buffer (pH 6) and
heated in a pressure cooker for 20 min, cooled for 5 min,
and washed in distilled water. Sections were next incu-
bated with anti-PrP SAF-84 (SPI bio; 1:400) for 45 min
followed by anti-mouse biotin (Jackson Immunolabs;
1:250) for 30 min, followed by streptavidin-HRP (Jackson
Immunolabs; 1:2000) for 30 min. Sections were then incu-
bated with DAB substrate and an enhancer (Invitrogen),
and counterstained with hematoxylin.
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Paraffin-embedded tissue (PET) blot
Five-μm thick sections were collected onto 0.45 μm nitro-
cellulose membranes (Biorad), dried at room temperature
overnight, and heated at 55 °C for 30 min. Membranes
were then incubated in xylene and serially rehydrated in
100%, 70% isopropanol, and distilled water with 0.1%
Tween-20 for 10 min each. To improve tissue adherence,
membranes were dried. After a brief rinse with TBST [10
mM Tris-HCl (pH 7.8), 100 mM NaCl, 0.05% Tween-20],
membranes were incubated in 50 μg/ml of PK in 10 mM
Tris-HCl (pH 7.8), 100 mM NaCl, 0.1% Brij-35 at 56 °C
for 16 h, washed twice in TBST, incubated in 4M guan-
idine isothiocyanate in 10 mM Tris-HCl for 30 min, and
washed in TBST. Membranes were blocked in casein
(Sigma-Aldrich) and immunolabelled with anti-PrP
monoclonal antibody SAF84 (Cayman Chemical) for two
hours, biotinylated goat anti-mouse IgG (Jackson Immu-
nolabs) for one hour, streptavidin-HRP (Jackson Immuno-
labs) for 30 min, and DAB substrate for 5 min. Color
development was stopped by immersing briefly in distilled
water and then membranes were dried overnight.
Western blotting and sodium phosphotungstic acid
precipitation
Brain tissue was homogenized in PBS using a Beadbea-
ter™ tissue homogenizer. Homogenates in a Tris-based
lysis buffer (10 mM Tris-HCl, 150 mM NaCl, 10 mM
EDTA, 0.5% NP40, 0.5% DOC; pH 7.4) were digested
with 50 μg/ml proteinase K at 37 °C for 30 min and the
reaction stopped by boiling samples for 5 min in LDS
loading buffer (Invitrogen). Samples were electropho-
resed in 10% Bis-Tris gel (Invitrogen) and transferred to
a nitrocellulose membrane by wet blotting. Membranes
were incubated with monoclonal antibody POM19
(discontinuous epitope at C-terminal domain, amino
acids 201–225 [37], a kind gift from Dr. Adriano Aguzzi)
followed by incubation with an HRP-conjugated anti-
mouse IgG secondary antibody (Jackson Immunolabs).
The blots were developed using a chemiluminescent
substrate (ECL detection kit, ThermoScientific) and
visualized on a Fuji LAS 4000 imager. Quantification of
PrPSc glycoforms was performed using Multigauge V3
software (Fujifilm).
PrPSc was concentrated from 87V and mCWD mouse
brain samples by performing sodium phosphotungstic
acid (NaPTA) precipitation prior to western-blotting [46].
Briefly, 100 μl aliquots of 10% brain homogenate in an
equal volume of 4% sarkosyl in PBS were incubated for 30
min, then digested with an endonuclease [Benzonase™
(Sigma)] followed by treatment with 100 μg/ml proteinase
K(50 μg/ml for WT brain) at 37 °C for 30 min. After
addition of NaPTA, MgCl2, and protease inhibitors
(Complete TM, Roche), extracts were incubated at 37 °C
for 30 min, and centrifuged at 18,000 g for 30 min at 37 °C.
Pellets were resuspended in 0.1% sarkosyl prior to
electrophoresis and blotting.
Prion uptake by primary neurons
Prions were partially purified by lysis in Tris buffered
saline containing 2% sarcosyl, then were digested with
an endonuclease for 30 min at 37 °C, and centrifuged at
18,000 g for 1 h. The pellets were washed and resus-
pended in PBS. Primary cortical neurons (200,000 cells)
from E18 WT or Prnp-/- mouse embryos were cultured
for a minimum of 6 days (in neurobasal media, 2% B27,
and 1X GlutaMAX™) [51, 52]. In brief, the cerebral
cortices were dissected, dissociated with 0.25% trypsin at
37 °C for 20 min, treated with DNase, and triturated.
Debris was removed by passing the cells through a 40
μm cell strainer. Cells were then centrifuged for 5 min
and resuspended in neurobasal media with 2% B27, 1X
GlutaMAX™. Following several days in culture, neurons
were then exposed to partially purified prions for time-
points from 0 - 48 h. At each timepoint, neurons were
washed three times with cold PBS, treated with 0.25%
trypsin for 3 min, centrifuged for 5 min at 2000 g,
washed in cold PBS, and centrifuged again prior to cell
lysis (10mM Tris-HCl, 150 mM NaCl, 1% sarcosyl).
Total protein concentration was measured and equal
protein amounts were assessed at each timepoint by
western blot for analysis of prion uptake. Immunoblot
signals were quantified using Multigauge V3 software
(Fujifilm). To calculate the percent uptake, the signal at
each timepoint was divided by the signal at the final
timepoint, which was considered 100%. A minimum of
three experimental replicates were performed.
Exposure of neurons to compounds interfering with
internalization
Cortical neurons from E18 mouse embryos were cultured
for 7 days. Dynasore (80 μM), cytochalasin D (2 μM),
amiloride (200 μM), 5-(N-ethyl-N-isopropyl)amiloride
(EIPA) (50 μM), rottlerin (30 μM), chlorpromazine (5 μg/
ml) in media were added to neurons for 30 min. Prions
were then added to the neurons for 3 h, and then cells
were washed three times with cold PBS and treated with
0.25% trypsin for 3 min to remove surface PrPSc. Media
was added and cells were collected and washed with PBS
prior to lysis with lysis buffer (Tris-HCl, 150 mM NaCl,
and 1% sarcosyl) and endonuclease treatment. Protein
concentration was measured and proteins were normal-
ized prior to proteinase K digestion and immunoblotting.
Six experimental replicates were performed for all com-
pounds except EIPA (3 replicates).
Retrograde axonal transport using microfluidic chambers
Cortical neurons were cultured from wild type (C57BL/6)
mouse E18 embryos. The cerebral cortices were dissected,
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dissociated with 0.25% trypsin at 37 °C for 20 min, treated
with DNase, and triturated. Debris was removed by pass-
ing the cells through a 40 μm cell strainer. Cells were then
centrifuged for 5 min and resuspended in neurobasal
media with 10% FBS, 2% B27, 1X GlutaMAX™. Approxi-
mately 25,000 neurons were loaded into the cell body
compartment of the polydimethylsiloxane microfluidic
chamber for protein biochemistry assays [47]. After 5 min,
the remaining compartments were filled with media. Cells
were maintained in maintenance medium (neurobasal
media with 2% B27 and 1X GlutaMAX™). The neurons
were grown in the microfluidic chambers for 6 days or
until neuronal projections extended into the axon
compartment. Subfibrillar or fibrillar prions were
added to the axon terminal compartment for 48 h.
Prions were removed after 48 h by washing, and cell
bodies and axons were collected 2 weeks later. The
axons and somas were each washed three times with
PBS. The soma chamber was washed by placing the
chamber with the soma compartment in a vertical
position and passing PBS through the somal well. The
somas were collected first by similarly holding the
chamber vertically and applying lysis buffer (10mM
Tris-HCl, 150 mM NaCl, 1% sarcosyl, benzonase™,
MgCl2) to the well and collecting the lysate. Axons
were next collected by adding lysis buffer to the axon
chamber. All chambers were assessed after use for
leakage using trypan blue dye.
RT-QuIC assay
RT-QuIC reaction mix was composed of 10 mM phos-
phate buffer (pH 7.4), 130 mM NaCl, 0.1 mg/ml recom-
binant mouse prion protein (residues 23-230 rPrPSen),
10 μM thioflavin T (ThT), 1 mM ethylenediaminetetra-
acetic acid tetrasodium salt (EDTA), and 0.001% SDS.
Aliquots of the reaction mix (98 μl) were loaded into
each well of a black 96-well plate with a clear bottom
(Nunc) and seeded with 2 μl of a 10-1 dilution of 22L,
87V or WT mouse brain-exposed neuronal lysates
(somas or axons). The plate was sealed (plate sealer film,
Nalgene Nunc International) and incubated at 42 °C in a
BMG FLUOstar Omega plate reader with cycles of 1 min
shaking (700 rpm double orbital) and 1 min rest. ThT
fluorescence measurements (450 +/- 10 nm excitation and
480 +/- 10 nm emission; bottom read) were taken every
45 min. To compensate for minor differences in baselines
between fluorescent plate readers and across multiple ex-
periments, data sets were normalized to a percentage of
the maximal fluorescence response (260,000 rfu) of the
plate readers after subtraction of the baseline and plotted
versus reaction time. Reactions were classified as RT-
QuIC positive based on a threshold set by 1.5 standard de-
viations from the average of the wild-type control brains
at 30 h (approximately 10% of ThT emission).
Prion solubility assay of PrPSc
Brain homogenates were solubilized in 1% sarcosyl in
PBS and digested with 50 μg/ml of proteinase K (final)
(WT) or 100 μg/ml (tga20) for 30 min at 37 °C. Protease
inhibitors were added (Complete TM™), and samples
were layered over 15% Optiprep™ and centrifuged at
18,000 g for 30 min at 4 °C. Supernatants were removed
and pellets were resuspended in PBS in a volume equiva-
lent to the supernatant. Supernatant and pellet fractions
were immunoblotted using anti-PrP antibody POM19
and PrP signals were captured and quantified using the
Fuji LAS 4000 imager and Multigauge V3.0 software.
Brain samples from 3-5 mice were measured per strain.
PrPSc disaggregation assay
The protocol was adapted from Deleault et al., 2008
[15]. In brief, 10% brain homogenate was solubilized in
1% sarcosyl in PBS for 30 min at 37 °C. 1% Triton X-100
in PBS was added and samples were ultracentrifuged at
100,000 g for 1 h at 4 °C. The supernatant was discarded
and pellets were resuspended in 1% Triton X-100 and
incubated for 2 h at 37 °C. After 2 h, samples were sub-
jected to sonication bursts of 10 s on and 30 s off at 80%
power in a high intensity sonicator bath (Misonix™ horn
sonicator) for a total sonication time of 3 min. Samples
(700 μl) were then layered over 15% Optiprep™ (300 μl)
and centrifuged at 10,000 g for 30 min at 4 °C. Pellets
were resuspended in 0.2% sarcosyl in PBS. PrPSc in the
supernatants was concentrated by sodium phosphotung-
stic acid (NaPTA) precipitation [46]. Samples were
immunoblotted using the anti-PrP POM19 antibody, an
HRP-conjugated anti-mouse IgG secondary antibody,
and a chemiluminescent substrate, and signals were cap-
tured on the Fuji LAS 4000 Imager and measured using
the Multi Gauge V3.0 software. Brain samples from 4-6
mice were measured per strain.
Assessing the size of recombinant PrP fibrils
Recombinant PrP fibrils were prepared by expression
and purification of mouse PrP (amino acids 23-144)
followed by fibrillization as previously described [29].
Fibrils were sonicated the same way as the brain homog-
enates: 80% power, 10 s on, 30 s off, for a total of 3 min
of sonication time. Negative stain electron microscopy
was performed to compare the unsonicated and the son-
icated fibril length. Fibrils were loaded onto a 100 mesh
copper grid, washed with PBS, and stained with 2%
uranyl acetate. Grids were imaged using transmission
electron microscopy on a Tecnai G2 Spirit BioTWIN
transmission electron microscope equipped with an
Eagle 4k HS digital camera (FEI). For quantification,
8-12 isolated fibrils from 12 images (93 and 147 unsoni-
cated and sonicated fibrils, respectively) were measured
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using ImageJ software (NIH). Sonicated and unsonicated
fibril lengths were compared using a Student’s t-test.
Prion fibril solubility assay
Fibrils were diluted to 0.4 mg/ml in PBS. Sonicated and
unsonicated fibrils were layered over 15% Optiprep™ and
centrifuged at 18,000 g for 30 min at 4 °C. Supernatants
were removed and pellets were resuspended in PBS in a
volume equivalent to the supernatant. Supernatant and
pellet fractions were immunoblotted using anti-PrP
antibody POM1 and PrP signals were captured and
quantified using the Fuji LAS 4000 imager and
Multigauge V3.0 software.
Statistics
Data are presented as mean ± SEM unless otherwise in-
dicated with group differences tested using standard
parametric methods (Student’s t-test, 2-tailed). P values
of less than 0.05 were considered statistically significant.
Results
Early entry and replication of subfibrillar prions in the
brainstem after an intra-tongue prion exposure
Distinct, sequence-matched PrPSc assemblies, or strains,
are associated with remarkably varied clinical and patho-
logic disease phenotypes [10, 19]. We first examined the
ability of diverse prions to spread from the tongue to the
brain using a panel of strains comprising primarily fibril-
lar (87V, mCWD) or subfibrillar assemblies (amorphous
oligomers or short fibrils) (22L, RML, ME7), which are
defined by whether fibrils are visible ultrastructurally in
the brain in situ [7, 26–28, 41]. The tongue is a natural
route for prion entry through abrasions [3], is highly in-
nervated, and provides a direct route for prion spread to
the brain via cranial nerves independent of a lymphoid
replication phase [2]. WT mice (VM/DK background)
and tga20 mice, which overexpress mouse PrP by 6-8
fold under the prion promoter [17], were used to investi-
gate prion spread (Methods detail the mice and prion
strains). After an intra-tongue (IT) injection, all three
subfibrillar prions induced a rapid progression to
terminal disease in 100% of mice, whereas neither fibril-
lar strain led to efficient prion spread to the CNS, with
either 0% or 11% of mice developing prion disease
(Fig. 1a-f ). A time course revealed initial replication of
subfibrillar prions in the brainstem (facial nucleus, re-
ticular formation and deep cerebellar nuclei) (Fig. 1a-b)
and lateral hypothalamus by 50% of the incubation
period (59 days post-inoculation), consistent with trans-
port from the tongue to the brain via cranial nerves and
spread to the hypothalamus. Clinically negative mice had
no histologically or biochemically detectable prions, even
following sodium phosphotungstic acid precipitation
[46] to increase the sensitivity of detection (Fig. 1f ). The
single mouse that developed prion disease following in-
oculation with 87V prions developed both plaques and
diffuse PrPSc deposits, similar to mice inoculated by the
IC route (Fig. 1e).
To exclude the possibility that PrP was replicating in
FDCs within lymphoid tissue and then spreading to the
brain, we inoculated mice that express PrP under the con-
trol of the neuron specific enolase (NSE) promoter with
three prion strains by either the IT or IC route. We found
that the subfibrillar prions, RML and ME7, spread from
the tongue to the brain, indicating that prion replication
in lymphoid tissue was not required for brain entry. The
fibrillar prion, mCWD, once again did not spread from
the tongue to the brain (Additional file 1: Figure S1).
Neuronal uptake of the subfibrillar and fibrillar prion
strains by macropinocytosis
To investigate the mechanism underlying the brain entry
observed for the subfibrillar but not the fibrillar prion
strains, we tested whether the neuronal uptake of prions
correlated with the level of soluble, non-sedimenting
prion particles, ie, the proteinase-K (PK)-resistant parti-
cles that remain suspended in 15% iodixanol following
centrifugation. We first measured the non-sedimenting
fraction of the five prion strains and found that the sub-
fibrillar strains showed significantly more soluble, non-
sedimenting particles than the fibrillar strains (P < 0.01)
(Additional file 2: Figure S2). We next tested prion
uptake by neurons. Using primary neurons, we found no
difference in the internalization of subfibrillar or fibrillar
prions (Fig. 2a, Additional file 3: Figure S3), and uptake
was independent of PrP expression, consistent with pre-
vious reports [32]. As the mechanism of uptake may
vary between the subfibrillar or fibrillar prion strains,
macropinocytotic- and clathrin-mediated endocytic
pathways were inhibited chemically. Macropinocytosis
inhibitors markedly decreased the internalization of both
subfibrillar and fibrillar prions, indicating that endocyto-
sis of prions occurs primarily via macropinocytosis
(Additional file 4: Figure S4). Inhibitors of clathrin-
mediated endocytosis had less of an effect on prion
uptake in primary neurons (Additional file 4: Figure S4).
Axonal transport of prions from the axon terminal to the
cell body
Given that neurons endocytose both subfibrillar and
fibrillar prions in vitro, yet only the subfibrillar prions
efficiently spread to the brain in vivo, we reasoned that
prions may differ in their capacity for axonal transport.
Therefore we next used neurons to examine the transit
of prion aggregates from the axon terminals to the cell
body. Neurons grown in microfluidic compartmentalized
chambers were exposed to subfibrillar or fibrillar prions,
or a mock control, for 48 h (Fig. 2b), and two weeks
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later the cell bodies were analyzed for PrPSc using the
highly sensitive and specific real-time quaking induced
conversion (RT-QuIC) assay [48]. As a control for leak-
age, microfluidic chambers lacking cells were exposed to
prions in the axonal compartment, and the cell body
compartments were assessed for prion seeding activity.
As a further control, all chambers were assessed for
leakage between compartments using trypan blue dye
and showed no dye in the cell body compartment.
Surprisingly, both the subfibrillar and fibrillar prion
strains were detected in the cell bodies in equal numbers
of experimental replicates (Fig. 2c). No prions were
detected in the mock (Fig. 2c) or in the prion-seeded,
cell-free control samples (data not shown). Collectively,
these results suggest that the fibril-forming prion strains
can transit in nerves, despite rare entry into the CNS in
vivo.
Increasing the particle number enhances neuroinvasion
of 87V prions
Our findings indicate that the fibrillar prion strains are
endocytosed and transported from the axon terminals to
the neuronal cell bodies in vitro, although rarely enter
the CNS in vivo. The in vitro exposure to the fibrillar
strains would flood the axon terminals with small and
large fibril fragments, whereas in vivo, the smaller,
Fig. 1 Fibrillar prion strains rarely neuroinvade following intra-tongue inoculation. a Schematic of time course experiment following IT exposure.
T1, and T2: 0.50 and 0.75 of the expected incubation period; T3: terminal disease (1.0). b Paraffin-embedded tissue (PET) blot of brainstem (T2 timepoint)
shows subfibrillar prions in the facial, reticular, and deep cerebellar nuclei (strain RML, left panel, arrows), whereas fibrillar prions were not detected at any
early timepoint (strain 87V, right panel). c Survival curves of WT or d tga20 mice (overexpress mouse PrPC) inoculated IT or IC with subfibrillar (blue - 22L,
RML, ME7) or fibrillar (red - 87V, mCWD) prion strains. e Brain immunolabelled for PrP shows diffuse prion aggregates or large dense plaques in mice
exposed to highly or poorly neuroinvasive prions, respectively. No plaques were detected in mice inoculated with mCWD IT (red box highlights brain
sections from mice inoculated with mCWD by the IC versus IT route). Percentage of IT-inoculated mice that developed terminal prion disease is noted.
Brain regions shown are as follows: cerebral cortex (IC: 22L); corpus callosum (IC: mCWD); thalamus (IC: 87V, RML, ME7; IT: 22L); hypothalamus (IT: ME7);
brainstem (IT: 87V, RML, mCWD). f Immunoblots of brain from T1, T2, and T3 timepoints post IT inoculation. “p” and “n” refer to prion positive and negative
brain samples (controls), and PK indicates proteinase K treatment. For IC inoculated mice, n= 4 (22L), 5 (87V, ME7, mCWD), or 6 (RML). For IT inoculated
mice, n= 8 (22L), 9 (87V), 6 (RML), 4 (ME7), or 5 (mCWD). Scale bar = 100 μm
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diffusible particles would likely travel faster through the
interstitial space to the axon terminals [40]. To test the
hypothesis that the level of small, diffusible prion parti-
cles impacts neuroinvasion, we exposed mice to a higher
dose of 87V fibrillar prions IT (10-fold increase). We
observed a 53% increase in the attack rate (number of
mice developing terminal disease) and the presence of
prion plaques in the cerebral cortex (Fig. 3a-b), indicat-
ing that the poor neuroinvasion was not due to an abso-
lute block in the capacity for neuroinvasion, but that
more prion particles or a higher titer, could enhance
neuroinvasion of 87V prions.
Increasing prion aggregate solubility enhances
neuroinvasion
We and others have found that sonication decreases prion
fibril size [13, 43], shifting the fibril population from a mix-
ture of short and long fibrils to more uniformly short fibrils
(Fig. 3c). In addition to decreasing the fibril size, sonication
also markedly increased the solubility of prion fibrils from
3% soluble to approximately 37% soluble (Fig. 3d). We next
assessed how sonication alters the solubility of brain-
derived prions using a modified disaggregation assay that
does not involve PK digestion to deplete the PrPC [15]. In
brief, samples were subjected to ultracentrifugation and the
pellet fraction was resuspended and divided into two tubes,
one of which was sonicated. All samples were then over-
layed onto 15% iodixanol, centrifuged at 10,000 g, and the
PrPSc was measured in the supernatant and pellet fractions.
We found that the soluble, non-sedimenting fraction of all
strains except mCWD significantly increased post-
sonication (Fig. 3e). In the case that the number of small
particles governs neuroinvasion, sonicating the prions while
maintaining the same absolute prion mass would be ex-
pected to increase spread to the CNS. Sonicating the 87V
fibrillar prions increased prions in the soluble fraction by
2.5 fold and significantly increased the attack rate, as 50%
of mice developed terminal prion infection and prion pla-
ques in the cerebral cortex (previously 11%). The mean in-
cubation period was slightly shorter than the single mouse
inoculated with the unsonicated prions (350 versus 374
days) (Fig. 3f). Our data suggest that a critical threshold of
small, soluble particles is required for prion propagation
into the CNS. Interestingly, the mCWD prions, which form
exclusively large dense plaques of long fibrils [41] and
primarily insoluble PrPSc aggregates, did not neuroinvade
Fig. 2 Subfibrillar and fibrillar prion strains are internalized and transported from the axon terminal to the soma. a Representative western blot
shows subfibrillar (22L, RML) or fibrillar (87V, mCWD) prion internalization over time. Mean and SE from four (22L, 87V) or three (RML, mCWD)
independent experiments. b Schematic of the microfluidic chamber in which the cells bodies reside in a large chamber and axons grow through
fine grooves into side chambers where prions are introduced. c RT-QuIC analysis reveals PrPSc in the soma of neurons whose axons were exposed
to subfibrillar (22L) or fibrillar (87V) prions, but not uninfected WT brain (WT). Shown are the mean and SE thioflavin T fluorescence signal for the
positive cell body samples collected two weeks after prion exposure (4 of 8 positive samples per strain). The 87V prions were detected by
RT-QuIC at slightly earlier times, which is not indicative of differences in the prion levels. Dashed line represents the threshold for positivity
(see Methods)
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following exposure of mice to either a higher prion concen-
tration or to sonicated prions (Additional file 5: Fig. S5).
Collectively, these results show that high levels of small,
soluble PrPSc particles correlates with the ability of a prion
to neuroinvade.
Discussion
Prion spread from tongue to brain is reported to be
highly efficient, occurring rapidly and without requiring
an initial replication phase in lymphoid tissue [2, 3, 6].
Consistent with these reports, we also found highly
efficient, rapid spread of prions from tongue to brain for
three subfibrillar strains. However, two fibrillar strains
either failed to spread, or rarely spread following an
intra-tongue challenge. Similar findings have been
reported for other fibrillar prions inoculated into the
tongue or other peripheral sites [5, 14], including GPI-
anchorless prion fibrils, which accumulate in the nerves
and muscle of the tongue, but fail to spread into the
brain following a tongue inoculation [30].
The poor spread of fibrillar prions into the brain was
unlikely due to a lack of prion uptake by neurons. In
primary neurons, fibrillar prion strains were readily in-
ternalized by macropinocytosis, similar to other protein
aggregates, such as SOD1 and tau [24, 49, 50]. Consist-
ent with our findings, Magalhães and colleagues showed
prion fibrils were internalized by neurons, and uptake
was independent of PrP expression [32]. In addition to
being internalized by neurons, the fibrillar 87V prion
strain could transit from the axon terminal to the cell
body in vitro, indicating that concentrated 87V prions
applied directly to axon terminals could be transported
within a neuron. This finding was consistent with the
single mouse developing prion disease after intra-tongue
Fig. 3 Increasing PrPSc concentration or sonicating prions increases neuroinvasion of fibrillar prion (strain 87V). a Survival curves of mice
inoculated with a 10-fold higher concentration of fibrillar 87V prions (high dose: solid red line) (10% IT: n = 13; 1% IT: n = 9; 1% IC: n = 5) (1% IC
and 1% IT mice are the same shown in Fig. 1c). b Representative western blot of brain shows proteinase-K (PK) resistant PrPSc in 3 of 5 mice
exposed IT to high dose 87V prions. c Representative images of recombinant PrP fibril ultrastructure show that sonication results in short
homogenous fibrils (mean length of unsonicated = 524 nm versus sonicated = 222 nm; P < 0.0001, Student’s t test). d Solubility assay on sonicated
and unsonicated fibrils shows that sonication increases the solubility of the fibrils. e Disaggregation assay. Western blots show the increase of
PK-resistant 22L and 87V prions in the supernatant following sonication of prion-infected brain homogenate. Quantification shows the results of
all strains. f Survival curve of mice inoculated with sonicated, low dose (1%) fibrillar 87V prions. n = 10 (1% sonic. IT), 9 (1% IT), 4 (1% sonic. IC).
The 9 mice inoculated with 1% prions IT are also shown in panel a and Fig. 1c. g Representative western blot of brain from mice exposed IT to
sonicated fibrillar 87V prions shows PK-resistant PrPSc in 3 of 5 mice. h PrPSc shows large dense plaques in the brains of mice (cerebral cortex)
exposed IC or IT to sonicated 87V prions. “n”: mock-inoculated brain control. Scale bars = 500 nm (c) and 100 μm (h)
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inoculation, and indicates that the 87V prion strain can,
in rare cases, transit into the CNS.
The failure of prion transport to the CNS in most
mice exposed to 87V prions may be due to limited ex-
posure of axon terminals to fewer small, soluble parti-
cles. When the PrPSc mass was held constant but the
particle sedimentation, and presumably size, of 87V
prions was reduced by sonication, prion neuroinvasion
profoundly increased. Since sonication does not alter
prion strain properties [15], the initial poor neuroinva-
sion of the fibrillar prions was not likely due to features
of the quaternary structure, surface chemistry, or other
biophysical properties of the 87V prions, but instead
was likely due to the low number of small, non-
sedimenting particles. Simply increasing the number of
smaller, non-sedimenting prion particles, while main-
taining the same PrPSc mass, enhanced neuroinvasion.
Was the increase in neuroinvasion simply due to a higher
prion titer post-sonication? Smaller subfibrillar prion parti-
cles were shown to have more infectivity than larger fibrils
when compared by mass of PrP [42]. Additionally, sonic-
ation likely increased the titer due to increasing the particle
number and “free ends” available for recruiting PrPC mono-
mers, and we observed an 18% decrease in incubation
period in IC-inoculated mice, consistent with a higher titer.
However, if a high titer is the primary determinant for prion
neuroinvasion, then GPI-anchorless RML fibrillar prions,
which develop to very high titers in blood and heart of
transgenic mice [45], should be highly neuroinvasive, even
more so than their RML counterpart. Yet this is not the
case, as GPI-prions are non-neuroinvasive by the intra-
tongue route [30], although a requirement of a GPI-anchor
for prion neuroinvasion cannot be excluded. High prion
titers do not seem to strictly correlate with neuroinvasion.
Although titer does not correlate well with neuroinva-
sion, it is worth considering that a higher local prion titer
in the tongue may increase prion replication locally and
enable prions to neuroinvade. We and others have shown
that prion neuroinvasion from the tongue does not
require initial replication in local or distal lymphoid tissue.
Additionally, mice exposed to the sonicated 87V prions
showed an incubation period very similar to the mouse
that developed infection from the non-sonicated prions
(0.05% difference), suggesting that there was no major
change in the incubation period due to any prolonged
initial local replication phase. We would argue that the
enhanced neuroinvasion observed with the sonicated 87V
prions was not due to the increased number of “free ends”
per se that enable a heightened peripheral replication
phase, but was instead due to a higher number of smaller,
soluble and diffusible particles that traverse the interstitial
space for nerve entry and axonal transport.
Pathogenic prions form a spectrum of small subfibrillar
to highly fibrillar aggregates. The findings reported here
may be most relevant to the highly fibrillar, plaque-forming
prions with few low density prion particles, similar to the
non-neuroinvasive mCWD strain. Bovine amyloidotic
spongiform encephalopathy (BASE) is thought to originate
as a sporadic prion disease of cattle and causes dense, con-
gophilic, fibrillar plaques in the brain [12]. BASE prions are
highly infectious to cattle after an IC exposure [31]. Inter-
estingly, an oral exposure of 16 cattle with 1-50 g of BASE
prion-infected brain, containing 106.9 LD50 / g, infected
only one animal that had been exposed to 50 g of prion-
infected brain (6% of exposed cattle) [36]. In this animal,
there were fine and coarse PrPSc aggregates in the neuropil,
but no fibrillar plaques in any brain section examined. Nei-
ther the second animal challenged with 50 g of brain, nor
any other animal, developed clinical disease or any detect-
able PrPSc. These findings suggest very rare entry of BASE
prions into the CNS from an extraneural site, and only
when the dose is exceedingly high. Similarly, variant CJD in
129M tg650 mice formed fibrillar plaques in the brain fol-
lowing IC inoculation, yet prions did not spread to the
brain following intraperitoneal inoculation, despite early
and persistent prion replication in the spleen [5]. Together
with our findings, these studies suggest that fibril-rich,
plaque-forming strains are inefficient at neuroinvasion.
Since at least some plaque forming strains replicate in per-
ipheral lymphoid tissues, the lack of neuroinvasion of such
subtypes may lead to persistent subclinical carriers of infec-
tious prions.
Conclusion
Taken together, these findings support a model in which
small, soluble prion particles shuttle between extraneural
organs and the CNS via peripheral nerves. Slowly sediment-
ing prion particles were previously found to be highly infec-
tious and a feature of strains that induce a rapidly lethal
disease [44]. Future studies may indicate whether an abun-
dance of small, more soluble particles distinguishes the
highly infectious prions from amyloids such as amyloid-β
and α-synuclein, which transit poorly from the eye or
tongue into the CNS, respectively [8, 16]. These findings
also suggest that therapeutic strategies designed to stabilize
fibrils [23, 33] may hinder the neuronal transport of prions,
and more generally other protein aggregates, thereby slow-
ing the progression of neurodegenerative disease.
Additional files
Additional file 1: Figure S1. (a) Survival curves of tg(NSE-PrP) mice
inoculated IC or IT with RML, ME7, or mCWD prions. N = 4 mice per
group for all groups except ME7 and mCWD IT where n = 5 mice. (b)
Immunoblots from RML-, ME7-, and mCWD-inoculated Tg(NSE-PrP) mice.
“n”: uninfected brain control. PK: proteinase K. (TIFF 5 kb)
Additional file 2: Figure S2. (a) Western blots show the solubility of
two prion strains, 22L (subfibrillar) and 87V (fibrillar). S: supernatant and
P: pellet. (b) Quantification of the pellet fraction for all five strains: 87V
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and 22L in WT mice (n = 5 mice each) and mCWD, ME7, and RML in
tga20 mice [n = 3 (mCWD) or 4 mice (ME7, RML)]. *P < 0.05 and **P < 0.01
for 87V versus 22L prions (Student’s unpaired, 2-tailed t-test) and for
tga20 mice (one-way ANOVA followed by Tukey multiple comparison
test). (TIFF 5 kb)
Additional file 3: Figure S3. Membrane bound prions are removed by
trypsin. Uninfected N2a cells were cooled to 4 °C for 10 min and then
exposed to partially purified 87V prions for 45 min at 4 °C. Cells were
then washed three times with cold PBS, exposed to 0.25% trypsin for 3
min, centrifuged for 5 min at 2000 g, and washed three times in cold
PBS prior to cell lysis, proteinase K digestion, and immunoblotting for
prion protein. (TIFF 1 kb)
Additional file 4: Figure S4. Prion uptake in neurons occurs primarily
by macropinocytosis. Primary neurons were exposed to prions after
chemically inhibiting macropinocytotic- (amiloride, EIPA, cytochalasin D,
rottlerin) and clathrin-mediated (dynasore) endocytic pathways. (a)
Western blot shows very low PrPSc in cells in which the macropinocytotic
pathways were inhibited. Note that dynasore, an inhibitor of clathrin-
mediated uptake, had little effect on 22L or 87V prions. (b) Quantification
of PrPSc uptake relative to the no drug control. Chlorpromazine was toxic
to the cells and was not quantified. ***P < 0.0001 for 22L and *P < 0.05
for 87V, repeated measures one-way ANOVA. Results from the Tukey
multiple comparison on the raw data are shown on the figure. Six
experimental replicates were performed for all inhibitors except for EIPA,
which had three replicates. (TIFF 4 kb)
Additional file 5: Figure S5. mCWD fibrillar prions did not neuroinvade
from the IT route following exposure to 10-fold higher concentration of
PrPSc. (a) Survival curves show that no mice died with detectable mCWD
prion plaques. (b) Western blots show no PK-resistant PrPSc in mice
inoculated by the IT route. (c) PrP immunohistochemical stains of brain
sections from mice exposed IT to 10% mCWD or 10% 87V. n:
mock-inoculated brain control. For mCWD mouse groups: n = 10 (1%
sonic.), 5 (10% IT), 5 (1% IT), 4 (1% IC). The mice inoculated with 1%
mCWD prions IT and IC are the same as those shown in Fig. 1C. Scale
bar = 100 μm. (TIFF 5 kb)
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